CA2799181C - Ospa chimeras and use thereof in vaccines - Google Patents

Ospa chimeras and use thereof in vaccines Download PDF

Info

Publication number
CA2799181C
CA2799181C CA2799181A CA2799181A CA2799181C CA 2799181 C CA2799181 C CA 2799181C CA 2799181 A CA2799181 A CA 2799181A CA 2799181 A CA2799181 A CA 2799181A CA 2799181 C CA2799181 C CA 2799181C
Authority
CA
Canada
Prior art keywords
seq
polypeptide
borrelia
ospa
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2799181A
Other languages
English (en)
French (fr)
Other versions
CA2799181A1 (en
Inventor
Brian A. Crowe
Ian Livey
Maria O'rourke
Michael Schwendinger
John J. Dunn
Benjamin J. Luft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxalta GmbH
Brookhaven Science Associates LLC
Baxalta Inc
Research Foundation of the State University of New York
Original Assignee
Baxalta GmbH
Brookhaven Science Associates LLC
Baxalta Inc
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Brookhaven Science Associates LLC, Baxalta Inc, Research Foundation of the State University of New York filed Critical Baxalta GmbH
Publication of CA2799181A1 publication Critical patent/CA2799181A1/en
Application granted granted Critical
Publication of CA2799181C publication Critical patent/CA2799181C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2799181A 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines Active CA2799181C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
US61/334,901 2010-05-14
PCT/US2011/036533 WO2011143623A1 (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines

Publications (2)

Publication Number Publication Date
CA2799181A1 CA2799181A1 (en) 2011-11-17
CA2799181C true CA2799181C (en) 2023-10-24

Family

ID=44121257

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2799181A Active CA2799181C (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines
CA2798331A Active CA2798331C (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2798331A Active CA2798331C (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines

Country Status (13)

Country Link
US (6) US8623376B2 (OSRAM)
EP (4) EP2569009B1 (OSRAM)
JP (6) JP6227407B2 (OSRAM)
KR (7) KR102085465B1 (OSRAM)
CN (3) CN107641151B (OSRAM)
AU (2) AU2011252850B2 (OSRAM)
BR (2) BR112012029058B1 (OSRAM)
CA (2) CA2799181C (OSRAM)
MX (3) MX375965B (OSRAM)
PL (2) PL2569008T3 (OSRAM)
RU (2) RU2636455C2 (OSRAM)
SI (2) SI2569008T1 (OSRAM)
WO (2) WO2011143623A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102085465B1 (ko) * 2010-05-14 2020-03-05 박스알타 인코퍼레이티드 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법
US20120123924A1 (en) 2010-10-20 2012-05-17 Mark Rose Virtual currency configuration apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
WO2013090611A2 (en) * 2011-12-13 2013-06-20 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
RU2015106742A (ru) * 2012-07-27 2016-09-20 Бакстер Интернэшнл Инк. Композиции, содержащие химерные молекулы ospa и способы их применения
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
EP2970410B1 (en) * 2013-03-15 2020-01-22 The Regents of The University of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
WO2015041710A1 (en) * 2013-09-23 2015-03-26 Ventria Bioscience, Inc. Ospa fusion protein for vaccination against lyme disease
RS59075B1 (sr) 2014-01-09 2019-09-30 Valneva Austria Gmbh Mutantni ospa fragmenti i postupci i upotrebe koji se odnose na njih
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
WO2016025331A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
KR102106547B1 (ko) * 2015-08-14 2020-05-06 텔레호낙티에볼라게트 엘엠 에릭슨(피유비엘) 패킷 데이터 네트워크 연결을 관리하기 위한 노드 및 방법
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
EP3609911B1 (en) * 2017-04-13 2023-07-05 Valneva Austria GmbH Multivalent ospa polypeptides and methods and uses relating thereto
JP7614842B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性エプスタインバーウイルスポリペプチド
WO2019195316A1 (en) 2018-04-03 2019-10-10 Sanofi Ferritin proteins
KR20210018206A (ko) 2018-04-03 2021-02-17 사노피 항원성 호흡기 세포융합 바이러스 폴리펩타이드
JP2021519599A (ja) * 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性ｏｓｐａポリペプチド
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
CA3174666A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improved methods of producing a lipidated protein
IL297166A (en) * 2020-04-09 2022-12-01 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use
WO2022133233A2 (en) 2020-12-17 2022-06-23 Idexx Laboratories, Inc. Rocky mountain spotted fever detection and treatment
WO2022261050A1 (en) * 2021-06-07 2022-12-15 The University Of Massachusetts Apparatus and method for continuous production of rna
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0536335A4 (en) 1990-06-15 1993-07-14 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ZA921025B (en) 1991-02-15 1992-11-25 Uab Research Foundation Structural gene of pneumococcal protein
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
ATE181572T1 (de) * 1991-08-15 1999-07-15 Smithkline Beecham Biolog Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
WO2002016422A2 (en) * 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Recombinant constructs of borrelia burgdorferi
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
DK0726955T3 (da) 1993-11-01 2004-08-09 Univ New York State Res Found Kimære proteiner, som omfatter Borreliapolypeptider, og anvendelser heraf
ATE225668T1 (de) 1996-02-12 2002-10-15 Cobra Therapeutics Ltd Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
KR20010020567A (ko) * 1997-06-30 2001-03-15 폴 지. 다이먼트 라임병 진단 및 예방을 위한 조성물용의 표면항원 및 단백질
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
DE602004019063D1 (de) 2003-04-02 2009-03-05 Us Gov Health & Human Serv Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi
MXPA05011110A (es) * 2003-04-16 2006-01-24 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
SI1730175T1 (sl) * 2004-03-24 2010-08-31 Merck Sharp & Dohme Optimiziran izraz hpv 52 l1 v kvasu
EP1768688A4 (en) 2004-07-02 2009-09-30 Raymond J Dattwyler ORAL BORRELIOSE VACCINE
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
AU2006320246A1 (en) 2005-11-29 2007-06-07 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP2129684B1 (en) 2007-02-22 2011-01-26 Baxter International Inc. Method of purification of hydrophobic proteins
EA201391788A1 (ru) * 2007-06-26 2014-08-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
WO2009099716A1 (en) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
US20110105355A1 (en) 2008-04-22 2011-05-05 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US20110262475A1 (en) 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
KR102085465B1 (ko) 2010-05-14 2020-03-05 박스알타 인코퍼레이티드 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법
RU2015106742A (ru) * 2012-07-27 2016-09-20 Бакстер Интернэшнл Инк. Композиции, содержащие химерные молекулы ospa и способы их применения

Also Published As

Publication number Publication date
US8623375B2 (en) 2014-01-07
CA2798331A1 (en) 2011-11-17
US9334311B2 (en) 2016-05-10
WO2011143617A1 (en) 2011-11-17
EP2569008A1 (en) 2013-03-20
WO2011143623A1 (en) 2011-11-17
US9303073B2 (en) 2016-04-05
RU2583289C2 (ru) 2016-05-10
EP2569009B1 (en) 2019-10-09
PL2569008T3 (pl) 2021-04-19
SI2569009T1 (sl) 2020-02-28
US20140141030A1 (en) 2014-05-22
RU2017138652A (ru) 2019-02-11
BR112012029058B1 (pt) 2022-03-29
EP3650041A1 (en) 2020-05-13
MX348113B (es) 2017-05-29
JP2016168057A (ja) 2016-09-23
JP2013529078A (ja) 2013-07-18
AU2011252850B2 (en) 2016-03-17
CN103118701A (zh) 2013-05-22
US20120020973A1 (en) 2012-01-26
RU2012153972A (ru) 2014-06-20
CA2798331C (en) 2022-03-15
CN103108652A (zh) 2013-05-15
BR112012027315A8 (pt) 2020-09-01
RU2636455C2 (ru) 2017-11-23
CN103118701B (zh) 2017-10-24
MX375965B (es) 2025-03-07
EP2569008B1 (en) 2019-12-25
KR102222869B1 (ko) 2021-03-04
EP2569009A1 (en) 2013-03-20
KR102085465B1 (ko) 2020-03-05
AU2011252844A1 (en) 2012-11-29
KR20180031814A (ko) 2018-03-28
CN103108652B (zh) 2016-05-11
BR112012027315A2 (pt) 2016-11-16
BR112012027315B1 (pt) 2021-08-17
JP2016171816A (ja) 2016-09-29
RU2012153752A (ru) 2014-06-20
KR102130584B1 (ko) 2020-07-07
US20110293652A1 (en) 2011-12-01
BR112012029058A2 (pt) 2020-06-23
JP2013529077A (ja) 2013-07-18
CA2799181A1 (en) 2011-11-17
US20160235830A1 (en) 2016-08-18
US9895434B2 (en) 2018-02-20
KR20130062954A (ko) 2013-06-13
KR102230562B1 (ko) 2021-03-22
US8623376B2 (en) 2014-01-07
MX2012013264A (es) 2014-12-05
KR20130133120A (ko) 2013-12-06
CN107641151A (zh) 2018-01-30
US20140141029A1 (en) 2014-05-22
JP6227407B2 (ja) 2017-11-08
US11305000B2 (en) 2022-04-19
EP3705133B1 (en) 2024-06-26
EP3705133A2 (en) 2020-09-09
AU2011252850A1 (en) 2012-11-29
KR20180082633A (ko) 2018-07-18
JP6965417B2 (ja) 2021-11-10
JP2020178719A (ja) 2020-11-05
EP3705133A3 (en) 2021-01-06
SI2569008T1 (sl) 2020-02-28
KR20190027955A (ko) 2019-03-15
MX340739B (es) 2016-07-22
JP6030052B2 (ja) 2016-11-24
RU2017138652A3 (OSRAM) 2021-03-15
PL2569009T3 (pl) 2020-06-15
KR20200084062A (ko) 2020-07-09
AU2011252844B2 (en) 2014-07-03
JP2018150386A (ja) 2018-09-27
KR20200024354A (ko) 2020-03-06
US20180296656A1 (en) 2018-10-18
CN107641151B (zh) 2021-10-01
MX2012013261A (es) 2013-04-19

Similar Documents

Publication Publication Date Title
US11305000B2 (en) Chimeric OspA genes, proteins and methods of use thereof
AU2018203336B2 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
HK40029362A (en) Ospa chimeras and use thereof in vaccines
HK40029422A (en) Ospa chimeras and use thereof in vaccines
HK1208627B (en) Compositions comprising chimeric ospa molecules and methods of use thereof
HK1183621A (en) Ospa chimeras and use thereof in vaccines
HK1183621B (en) Ospa chimeras and use thereof in vaccines
HK1183622A (en) Ospa chimeras and use thereof in vaccines
HK1183622B (en) Ospa chimeras and use thereof in vaccines

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160512

EEER Examination request

Effective date: 20160512

EEER Examination request

Effective date: 20160512

EEER Examination request

Effective date: 20160512

EEER Examination request

Effective date: 20160512

EEER Examination request

Effective date: 20160512

EEER Examination request

Effective date: 20160512

EEER Examination request

Effective date: 20160512

EEER Examination request

Effective date: 20160512